TapImmune to Sponsor Phase 1 Breast Cancer Vaccine Trial Following Recent FDA Approval of Investigational New Drug Application

SEATTLE, WA & Rochester, Minn. TapImmune Inc. (OTCBB: TPIV), a leading biotechnology company developing immunotherapies, today announced that following FDA IND approval, it will sponsor a Phase I HER-2/neu targeted therapeutic vaccine trial in HER-2/neu positive breast cancer patients at the Mayo Clinic. The trial stems from a technology license option and sponsored research agreements…

Details

TapImmune Inc to Present at Aegis Capital Emerging Growth Conference in Las Vegas on April 30 2011

SEATTLE, WA TapImmune Inc. (OTCBB: TPIV), a biotechnology company specializing in the development of immunotherapeutics and vaccines in the areas of oncology and infectious disease, today announced its Chairman and CEO, Dr. Glynn Wilson, will present at the Aegis Capital Emerging Growth Conference on Saturday, April 30. The conference will take place between April 28…

Details

TapImmune Provides Corporate Update

Seattle WA, TapImmune Inc. (OTCBB: TPIV), is pleased to provide this corporate update to our current and future shareholders and other interested parties. Our collaborative development programs for a breast cancer vaccine and for a new generation of smallpox vaccines are proceeding on schedule. We anticipate that an IND for the first Phase I study…

Details

TapImmune Inc. Featured in the March 11 Issue of the Financial Hub, www.cpreports.com

SEATTLE (GLOBE NEWSWIRE) — The article (http://www.cpreports.com/?p=931), written by respected business writer Gene Marcial, provides insights into recent progress of TapImmune Inc. (OTCBB:TPIV), its research and development collaborations and the status of the Company’s product portfolio. The article also discusses the current market cap and potential market cap of the Company and predicts the Company’s…

Details

Status of Clinical Development Clarification

Seattle WA, TapImmune Inc. (OTCBB: TPIV), wishes to provide a clarification to the Press Release issued on March 1, 2011 ‘TapImmune Closes $1.16 Million Funding’ We mistakenly stated in the footnote ‘About TapImmune’ section that “TapImmune is in clinical development of a vaccine technology to treat HER-2/neu positive breast cancer”. Our statement should have read…

Details

TapImmune Appoints New Personnel to Board of Directors and Advisory Team

Seattle WA, TapImmune Inc. (OTCBB: TPIV), is pleased to announce the following appointment to its Board of Directors: Lynn M. DePippo, Founder and Managing Partner, Sherbrook Capital Management. Previous appointments include Portfolio Manager Small Cap Equities at Citibank, Senior Investment Analyst at The Kaufmann Fund, NY, and Healthcare Services Analyst at Kidder Peabody and Company,…

Details